Core Insights - X4 Pharmaceuticals will report its financial results for Q1 2025 on May 1, 2025, and provide corporate updates [1] - A conference call and webcast will be held on the same day at 8:30 a.m. EDT for investors [2] Company Overview - X4 Pharmaceuticals focuses on developing innovative therapies for rare immune system diseases with significant unmet needs [3] - The company has developed mavorixafor, an orally available CXCR4 antagonist, currently marketed in the U.S. as XOLREMDI® [3] - X4 is conducting a global pivotal Phase 3 clinical trial (4WARD) for mavorixafor in patients with certain chronic neutropenic disorders [3]